Finland
GlucoModicum Ltd, established in 2018 as a spinout from the University of Helsinki, is revolutionizing glucose monitoring through its innovative needle-free magnetohydrodynamic technology. Situated in Finland, this startup is at the forefront of creating accessible and precise health monitoring solutions, addressing significant pain points in diabetes care through its non-invasive, wearable glucose monitor.
Utilizing a proprietary platform, GlucoModicum targets the growing demand for more convenient and less invasive health monitoring technologies. Backed by a multidisciplinary team and robust industry partnerships, the company anchors its potential in drastically improving diabetes management.
In its Venture Round on June 16, 2021, the venture garnered support from the European Innovation Council, evidencing strong credibility and interest from notable investors. GlucoModicum presents a promising investment opportunity through its pioneering approach and the universal need for improved diabetes solutions.
Echo Therapeutics
